Sarepta Therapeutics Stock Today
SRPT Stock | USD 117.89 0.60 0.51% |
Performance1 of 100
| Odds Of DistressLess than 13
|
Sarepta Therapeutics is selling for under 117.89 as of the 18th of April 2024; that is 0.51 percent up since the beginning of the trading day. The stock's last reported lowest price was 115.93. Sarepta Therapeutics has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but did not have a good performance during the last 90 trading days. Equity ratings for Sarepta Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 19th of March 2024 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 3rd of June 1997 | Category Healthcare | Classification Health Care |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. The company has 93.86 M outstanding shares of which 4.6 M shares are at this time shorted by private and institutional investors with about 5.23 trading days to cover. More on Sarepta Therapeutics
Follow Valuation Options Odds of Bankruptcy
Financial Report 7th of May 2024
Sarepta Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Sarepta Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Sarepta Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO President | Douglas Esq | ||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
Average Analyst Recommendation Analysts covering Sarepta Therapeutics report their recommendations after researching Sarepta Therapeutics' financial statements, talking to executives and customers, or listening in on Sarepta Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Sarepta Therapeutics. The Sarepta consensus assessment is calculated by taking the average forecast from all of the analysts covering Sarepta Therapeutics. | |||||
Sarepta Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Sarepta Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | |||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Sarepta Therapeutics' financial leverage. It provides some insight into what part of Sarepta Therapeutics' total assets is financed by creditors.
|
Sarepta Therapeutics (SRPT) is traded on NASDAQ Exchange in USA. It is located in 215 First Street, Cambridge, MA, United States, 02142 and employs 1,314 people. Sarepta Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 10.94 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sarepta Therapeutics's market, we take the total number of its shares issued and multiply it by Sarepta Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Sarepta Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 93.86 M outstanding shares of which 4.6 M shares are at this time shorted by private and institutional investors with about 5.23 trading days to cover.
Sarepta Therapeutics currently holds about 2.07 B in cash with (500.99 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 23.61.
Check Sarepta Therapeutics Probability Of Bankruptcy
Ownership AllocationSarepta Therapeutics maintains a total of 93.86 Million outstanding shares. The majority of Sarepta Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sarepta Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sarepta Therapeutics. Please pay attention to any change in the institutional holdings of Sarepta Therapeutics as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Sarepta Ownership Details
Sarepta Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Sarepta Therapeutics jumping above the current price in 90 days from now is about 89.45%. The Sarepta Therapeutics probability density function shows the probability of Sarepta Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Sarepta Therapeutics has a beta of 0.5783. This usually implies as returns on the market go up, Sarepta Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Sarepta Therapeutics will be expected to be much smaller as well. Additionally, sarepta Therapeutics has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Sarepta Therapeutics to move above the current price in 90 days from now is about 89.45 (This Sarepta Therapeutics probability density function shows the probability of Sarepta Stock to fall within a particular range of prices over 90 days) .
Sarepta Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Sarepta Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Sarepta Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Sarepta Therapeutics' value.Instituion | Recorded On | Shares | |
Geode Capital Management, Llc | 2023-12-31 | 1.5 M | |
Morgan Stanley - Brokerage Accounts | 2023-12-31 | 1.4 M | |
Jpmorgan Chase & Co | 2023-12-31 | 1.3 M | |
Citadel Advisors Llc | 2023-09-30 | 1.2 M | |
Bank Of America Corp | 2023-12-31 | 1.2 M | |
Farallon Capital Management, L.l.c. | 2023-12-31 | 1.2 M | |
Pictet Asset Manangement Sa | 2023-12-31 | 1.1 M | |
Casdin Capital, Llc | 2023-12-31 | 1 M | |
Norges Bank | 2023-12-31 | 836.8 K | |
Vanguard Group Inc | 2023-12-31 | 8.8 M | |
Blackrock Inc | 2023-12-31 | 6.2 M |
Sarepta Therapeutics Historical Income Statement
Sarepta Therapeutics Income Statement is one of the three primary financial statements used for reporting Sarepta's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Sarepta Therapeutics revenue and expense. Sarepta Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Sarepta Therapeutics' Cost Of Revenue is comparatively stable compared to the past year. Income Tax Expense is likely to gain to about 16.7 M in 2024, despite the fact that EBITDA is likely to grow to (254.4 M). View More FundamentalsSarepta Stock Against Markets
Picking the right benchmark for Sarepta Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Sarepta Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Sarepta Therapeutics is critical whether you are bullish or bearish towards Sarepta Therapeutics at a given time. Please also check how Sarepta Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Sarepta Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Watchlist Optimization Now
Watchlist OptimizationOptimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
All Next | Launch Module |
Sarepta Therapeutics Corporate Directors
Sarepta Therapeutics corporate directors refer to members of a Sarepta Therapeutics board of directors. The board of directors generally takes responsibility for the Sarepta Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Sarepta Therapeutics' board members must vote for the resolution. The Sarepta Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.Hans Wigzell | Independent Director | Profile | |
Michael Bonney | Director | Profile | |
Mary Gray | Director | Profile | |
Anthony Chase | Independent Director | Profile |
How to buy Sarepta Stock?
Before investing in Sarepta Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Sarepta Therapeutics. To buy Sarepta Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Sarepta Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Sarepta Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Sarepta Therapeutics stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Sarepta Therapeutics stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Sarepta Therapeutics, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.
Already Invested in Sarepta Therapeutics?
The danger of trading Sarepta Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Sarepta Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Sarepta Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Sarepta Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Sarepta Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Sarepta Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Sarepta Therapeutics Stock. Highlighted below are key reports to facilitate an investment decision about Sarepta Therapeutics Stock: Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Complementary Tools for Sarepta Stock analysis
When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Sarepta Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sarepta Therapeutics. If investors know Sarepta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sarepta Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.80) | Revenue Per Share 13.456 | Quarterly Revenue Growth 0.535 | Return On Assets (0.05) | Return On Equity (0.86) |
The market value of Sarepta Therapeutics is measured differently than its book value, which is the value of Sarepta that is recorded on the company's balance sheet. Investors also form their own opinion of Sarepta Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sarepta Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sarepta Therapeutics' market value can be influenced by many factors that don't directly affect Sarepta Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sarepta Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sarepta Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sarepta Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.